Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up.

OBJECTIVE To report the outcomes and late toxicities in younger patients with long-term follow-up treated with brachytherapy with or without external beam radiotherapy for prostate adenocarcinoma. MATERIALS AND METHODS Patients treated with brachytherapy with or without external beam radiotherapy who were aged ≤ 60 years at treatment with ≥ 10 years of follow-up were selected from our database. The outcomes were analyzed regarding biochemical failure, distant metastases, and cause of death. Genitourinary outcomes were assessed using the International Prostate Symptom Score, Radiation Therapy Oncology Group, and Common Terminology Criteria for Adverse Events criteria. Gastrointestinal toxicity was measured using Radiation Therapy Oncology Group scales. Erectile dysfunction was measured using Sexual Health Inventory for Men and the Mount Sinai Erectile Function score. RESULTS A total of 131 patients met the inclusion criteria, with a median age of 57 years at treatment and a median follow-up of 11.5 years. Of the patients in this cohort, 9.9% developed biochemical failure with 1 failure and 1 prostate cancer-related death after 10 years. The International Prostate Symptom Score were statistically unchanged after 10 years. Of 22 cases (17%) of grade 2 or greater genitourinary toxicities, only 6 (4.5%) continued after 10 years. Of 11 cases (8.3%) of grade 2 or greater gastrointestinal events, none persisted past 10 years. A significant decrease occurred in the mean Sexual Health Inventory for Men score from 19.5 to 15.3 (P = .008). Of the potent patients before treatment, 69% remained potent at last follow-up. A total of 4 second malignancies were detected, 2 of which were within the radiation field. CONCLUSION Men <60 years old who underwent brachytherapy for prostate cancer can expect minimal late genitourinary and gastrointestinal toxicity after 10 years and excellent potency preservation.

[1]  J. Battermann,et al.  Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[2]  H. Sandler,et al.  Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. , 2010, International journal of radiation oncology, biology, physics.

[3]  R. Stock,et al.  Factors influencing urinary symptoms 10 years after permanent prostate seed implantation. , 2012, The Journal of urology.

[4]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[5]  Adam P Dicker,et al.  Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group , 2012, BJU international.

[6]  Stephen E M Langley,et al.  Long‐term toxicity and quality of life up to 10 years after low‐dose rate brachytherapy for prostate cancer , 2012, BJU international.

[7]  Jette Borg,et al.  10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. , 2011, International journal of radiation oncology, biology, physics.

[8]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[9]  R. Stock,et al.  Long‐term potency preservation following brachytherapy for prostate cancer , 2010, BJU international.

[10]  J. Concato,et al.  Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis , 2003, Cancer.

[11]  C. Begg,et al.  Physician visits prior to treatment for clinically localized prostate cancer. , 2010, Archives of internal medicine.

[12]  M. Cooperberg,et al.  Impact of age at diagnosis on prostate cancer treatment and survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Schellhammer,et al.  Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer. , 2010, The Journal of urology.

[14]  R. Stock,et al.  Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. , 2005, Brachytherapy.

[15]  H. G. van der Poel,et al.  Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Platz,et al.  Prevalence and risk factors for erectile dysfunction in the US. , 2007, The American journal of medicine.

[17]  Alan W Partin,et al.  Treatment decision‐making for localized prostate cancer: What younger men choose and why , 2012, The Prostate.

[18]  R. Stock,et al.  Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.